FINWIRES · TerminalLIVE
FINWIRES

ASX:BUB

5 stories mentioning ASX:BUBUpdated 16d ago

Every FINWIRES story that references ASX:BUB, newest first.

What's the latest news on ASX:BUB?

Asia

Australian Shares Flat; Ingenia Communities Rejects Unsolicited Warburg Pincus Takeover Proposal

Australian shares were flat on Monday as concerns over global oil supplies lifted crude oil prices.The S&P/ASX 200 Index was little changed to close at 9,010.90.Brent crude oil futures rose to trade around $96 per barrel after the US hit three Iranian tankers and Iran launched missiles at two US Navy ships. Iron ore prices rose to $100 per tonne for the first time in a month.US employment data came in strong, boosting odds of a Federal Reserve rate hike.On the domestic front, ANZ-Indeed Australian Job Ads, a monthly indicator that tracks the total number of internet job advertisements across select websites, rose by a seasonally adjusted 2.5% month over month in August following an upwardly revised 1.9% increase in July, ANZ Research said.The value of new payments platform transactions in Australia jumped nearly 25% year over year to AU$260.6 billion in July, according to retail payment data from the Reserve Bank of Australia.In company news, Ingenia Communities Group (ASX:INA) rejected an unsolicited AU$4.75 per security cash takeover proposal from Warburg Pincus, saying the offer "substantially undervalues" the company and is not in the best interests of its security holders. Its shares rose nearly 15% on market close.Bubs Australia (ASX:BUB) has secured permanent US Food and Drug Administration (FDA) approval for its Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential infant formula products. Its shares closed up 30%.Lastly, Corporate Travel Management (ASX:CTD) and its former auditor, PricewaterhouseCoopers Australia, face a potential class action alleging the company misled investors in annual financial reports from 2020 to 2024, law firm Phi Finney McDonald said.

ASX 200ASX:BUBASX:CTDASX:INA
Asia

Bubs Australia Secures Permanent US FDA Approval for Three Infant Formula Products; Shares Up 35%

Bubs Australia (ASX:BUB) has secured permanent US Food and Drug Administration (FDA) approval for its Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential infant formula products, according to a Monday filing with the Australian bourse.The approval confirms the company's compliance with strict US safety, nutritional and quality standards, reinforcing its position as the only Australian infant formula brand authorized to supply the US market, the filing added.The company's shares jumped 35% in recent Monday trade.

ASX:BUB
Asia

Bubs Australia CFO Resigns

Bubs Australia (ASX:BUB) said Chief Financial Officer Naomi Verloop has resigned, according to a Friday filing with the Australian bourse.Chris Rowe has been appointed as the company's CFO, the filing said.Rowe most recently served as president of business-to-business and CFO at Darigold, the filing added.The company's shares rose around 2% in recent Friday trade.

ASX:BUB
Asia

Bubs Australia Issues Fresh Fiscal 2026 Outlook Amid Impact of Middle East Conflict, Competitive Pressures

Bubs Australia (ASX:BUB) expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$4 million to AU$8 million on revenue of AU$105 million to AU$115 million, according to a Friday filing with the Australian bourse.The company previously forecast fiscal year 2026 underlying EBITDA of AU$6.1 million on net revenue of AU$120 million to AU$125 million, according to a November 2025 filing.The company said it has worked to mitigate the impact of a range of external factors, including a shifting regulatory environment, product availability constraints, the Middle East conflict, and competitive pressures."That has meant carrying additional costs in the short term, but it has also allowed us to move quickly and position the business to meet our growth ambitions," said CEO Joe Coote.

ASX:BUB
Asia

Bubs Australia's Fiscal Q3 Net Revenue Rises 10% Year on Year, Shares Fall 7%

Bubs Australia's (ASX:BUB) fiscal third-quarter net revenue came in at AU$25.5 million, jumping 10% from the AU$23.2 million in the year-ago quarter, according to a Thursday Australian bourse filing.The US remained the group's largest revenue contributor in the quarter. Its total store distribution in the US rose by around 98% since 2025 and is projected to grow a further 23% by the first quarter of fiscal year 2027.During the period, the firm prioritized inventory allocation to higher-growth markets, resulting in rest-of-world revenue of AU$1 million, down 52% on the prior corresponding period.Its shares fell 7% in recent trading on Thursday.

ASX:BUB

Track with the FINWIRES app suite